Show simple item record

dc.contributor.authorMitin, T
dc.contributor.authorChoudhury, Ananya
dc.date.accessioned2018-10-22T21:07:37Z
dc.date.available2018-10-22T21:07:37Z
dc.date.issued2018-09-14
dc.identifier.citationThe role of biomarkers in bladder preservation management of muscle-invasive bladder cancer. 2018, World J Urolen
dc.identifier.issn1433-8726
dc.identifier.pmid30218307
dc.identifier.doi10.1007/s00345-018-2480-7
dc.identifier.urihttp://hdl.handle.net/10541/621305
dc.description.abstractPatients with localized muscle-invasive bladder cancer (MIBC) can choose to undergo either neoadjuvant chemotherapy followed by radical cystectomy or radiation therapy-based bladder preservation treatment modality with subsequent close cystoscopic surveillance with salvage cystectomy reserved for patients with evidence of local disease recurrence. At the present time, the decision regarding bladder-directed local therapy for MIBC is based on physicians' and patients' preferences, and does not take into account tumor biology. Predictive biomarkers, once validated, could offer a more patient-centered and biology-driven selection of bladder-directed therapies.
dc.language.isoenen
dc.rightsArchived with thanks to World journal of urologyen
dc.titleThe role of biomarkers in bladder preservation management of muscle-invasive bladder cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiation Medicine, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAen
dc.identifier.journalWorld Journal of Urologyen
html.description.abstractPatients with localized muscle-invasive bladder cancer (MIBC) can choose to undergo either neoadjuvant chemotherapy followed by radical cystectomy or radiation therapy-based bladder preservation treatment modality with subsequent close cystoscopic surveillance with salvage cystectomy reserved for patients with evidence of local disease recurrence. At the present time, the decision regarding bladder-directed local therapy for MIBC is based on physicians' and patients' preferences, and does not take into account tumor biology. Predictive biomarkers, once validated, could offer a more patient-centered and biology-driven selection of bladder-directed therapies.


This item appears in the following Collection(s)

Show simple item record